Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 13;11(7):530. doi: 10.1038/s41419-020-2719-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a CCK-8 assay for MDA-MB-231 and MDA-MB-468 cells cultured with control, pCMV-Flag-YAP-5SA (activated YAP), 5 nM docetaxel (Doc), 5 μM vinorelbine (Vin), pCMV-Flag-YAP-5SA and Doc or Vin for 48 hours. Control group vs YAP group (P = 0.005); Doc group vs Doc + YAP group (P = 0.030); Vin group vs Vin + YAP group (P = 0.036). The rest of the CCK-8 assays were similar to those described above. b Control group vs YAP group (P = 0.004); Doc group vs Doc + YAP group (P = 0.005); Vin group vs Vin + YAP group (P < 0.001). c pcDNA3.0-β-catenin was used for β-catenin overexpression. Control group vs β-catenin group (P < 0.001); Doc group vs Doc + β-catenin group (P = 0.029); Vin group vs Vin + β-catenin group (P = 0.010). d Control group vs β-catenin group (P = 0.004); Doc group vs Doc + β-catenin group (P = 0.005); Vin group vs Vin + β-catenin group (P < 0.001). e, f siRNA-YAP was used for YAP knockdown. Control group vs si-YAP group (P < 0.001); Doc group vs Doc + si-YAP group (P < 0.001); Vin group vs Vin + si-YAP group (P < 0.001). g, h Control group vs si-β-catenin group (P < 0.001); Doc group vs Doc + si-β-catenin group (P < 0.001); Vin group vs Vin + si-β-catenin group (P < 0.001). The data are presented as the mean ± SD of experiments performed in triplicate. Tumour formation assays in nude mice subcutaneously injected with MDA-MB-231 cells. The specific treatment was performed as described in the “Materials and Methods”. i Photograph of the tumour tissue. j Tumour growth was assessed every 3 or 6 days until treatment day 21 by measuring two perpendicular diameters and calculating the volume. Doc, docetaxel; Vin, vinorelbine; sh-YAP, lentiviral vector of YAP shRNA; sh-β-catenin, lentiviral vector of β-catenin shRNA. The data presented are means ± SDs; error bars represent the SD from five mice. Control group vs different treatment groups (P < 0.001). Statistical significance was determined using Student’s t test and one-way ANOVA test analysis.